Mathias Strowski

Dr. Mathias Strowski

Department of Hepatology and Gastroenterology, Charité-University Medicine Berlin, 13353 Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Molecular Endocrinology
Verified
Journal Article
Closed access
Mathias StrowskiMathias Strowski
Mathias Strowski
MKMartin Kohler
Martin Kohler
HCHoward Y. Chen
Howard Y. Chen
MTMyrna E. Trumbauer
Myrna E. Trumbauer
ZLZhihua Li
Zhihua Li
HWHilary A. Wilkinson
Hilary A. Wilkinson
Somatostatin (SRIF) regulates pancreatic insulin and glucagon secretion. In the present study we describe the generation of SRIF receptor subtype 5 knockout (sst(5) KO) mice to examine the role of SRIF receptor subtypes (sst) in regulating insulin secretion and glucose homeostasis. Mice deficient in sst(5) were viable, fertile, appeared healthy, and displayed no obvious phenotypic abnormalities. Pancreatic islets isolated from sst(5) KO mice displayed increased total insulin content as compared with islets obtained from wild-type (WT) mice. Somatostatin-28 (SRIF-28) and the sst(5)/sst(1)-selective agonist compound 5/1 potently inhibited glucose-stimulated insulin secretion from WT islets. SRIF-28 inhibited insulin secretion from sst(5) KO islets with 16-fold less potency while the maximal effect of compound 5/1 was markedly diminished when compared with its effects in WT islets. sst(5) KO mice exhibited decreased blood glucose and plasma insulin levels and increased leptin and glucagon concentrations compared with WT mice. Furthermore, sst(5) KO mice displayed decreased susceptibility to high fat diet-induced insulin resistance. The results of these studies suggest sst(5) mediates SRIF inhibition of pancreatic insulin secretion and contributes to the regulation of glucose homeostasis and insulin sensitivity. Our findings suggest a potential beneficial role of sst(5) antagonists for alleviating metabolic abnormalities associated with obesity and insulin resistance.

27 January 2020 in Molecules
Verified
Journal Article
Open access
PDF file
MJMariami Jasaszwili
Mariami Jasaszwili
MBMaria Billert
Maria Billert
Mathias StrowskiMathias Strowski
Mathias Strowski
KNKrzysztof W. Nowak
Krzysztof W. Nowak
Marek SkrzypskiMarek Skrzypski
Marek Skrzypski
Adropin is a unique hormone encoded by the energy homeostasis-associated (Enho) gene. Adropin is produced in the liver and brain, and also in peripheral tissues such as in the heart and gastrointestinal tract. Furthermore, adropin is present in the circulatory system. A decade after its discovery, there is evidence that adropin may contribute to body weight regulation, glucose and lipid homeostasis, and cardiovascular system functions. In this review, we summarize and discuss the physiological, metabolic, and pathophysiological factors regulating Enho as well as adropin. Furthermore, we review the literature addressing the role of adropin in adiposity and type 2 diabetes. Finally, we elaborate on the role of adropin in the context of the cardiovascular system, liver diseases, and cancer.

1 May 2008 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
Mathias StrowskiMathias Strowski
Mathias Strowski
ABAllan D. Blake
Allan D. Blake

21 April 2011 in Diabetologia
Verified
Journal Article
Closed access
PDF file
Marek SkrzypskiMarek Skrzypski
Marek Skrzypski
TLT. T. Le
T. T. Le
PKP. Kaczmarek
P. Kaczmarek
EPEwa Pruszynska-Oszmalek
Ewa Pruszynska-Oszmalek
PPP. Pietrzak
P. Pietrzak
Mathias StrowskiMathias Strowski
Mathias Strowski

22 December 2012 in Diabetologia
Verified
Journal Article
Open access
PDF file
AMAyman Mahmoud
Ayman Mahmoud
PKP. Kaczmarek
P. Kaczmarek
Marek SkrzypskiMarek Skrzypski
Marek Skrzypski
EPEwa Pruszynska-Oszmalek
Ewa Pruszynska-Oszmalek
Paweł KołodziejskiPaweł Kołodziejski
Paweł Kołodziejski
Mathias StrowskiMathias Strowski
Mathias Strowski
Glucagon reduces body weight by modifying food intake, glucose/lipid metabolism and energy expenditure. All these physiological processes are also controlled by fibroblast growth factor 21 (FGF-21), a circulating hepatokine that improves the metabolic profile in obesity and type 2 diabetes. Animal experiments have suggested a possible interaction between glucagon and FGF-21 however, the metabolic consequences of this crosstalk are not understood.

10 July 2009 in Gut
Verified
Journal Article
Closed access
PDF file
Mathias StrowskiMathias Strowski
Mathias Strowski
BWBertram Wiedenmann
Bertram Wiedenmann